Frankfurt
14.07.26 | 08:45
25,680 Euro
+2,39 % +0,600
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 23,220 | 23,620 | 10:08 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:14 | Xvivo Perfusion AB Q2 Profit Rises | 2 | RTTNews | ||
| 07:58 | XVIVO übertrifft im Q2 die Umsatzerwartungen dank starkem Thorax-Geschäft | - | Investing.com Deutsch | ||
| 07:50 | XVIVO Perfusion AB: Interim Report January - June 2026 | 206 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2026 (Apr-Jun)Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth... ► Artikel lesen | |
| 07:30 | Xvivo Perfusion AB: Interim report January - June 2026 | 6 | GlobeNewswire (Europe) | Second quarter 2026 (Apr-Jun)• Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth of 34 percent in SEK.• Organic growth was 36 percent in local currencies. Excluding revenue... ► Artikel lesen | |
| Do | OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S. | 275 | Business Wire | OneLegacy, the nonprofit organ procurement organization serving Southern California, announced the launch of the first in-house Ex Vivo Lung Perfusion (EVLP) program at an organ procurement organization... ► Artikel lesen | |
| 26.06. | XVIVO Perfusion AB: Conference call on Interim Report April-June 2026 | 371 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 26, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2026. The... ► Artikel lesen | |
| 18.05. | XVIVO Perfusion AB: Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology | 364 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 18, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 27.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 299 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV):The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB (publ) GAAP EPS of SEK1.15, revenue of SEK241M | 1 | Seeking Alpha | ||
| 24.04. | XVIVO Perfusion AB: Interim Report January - March 2026 | 182 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding to growth... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB: Interim Report January - March 2026 | 195 | GlobeNewswire (Europe) | First quarter 2026 (Jan-Mar)• Net sales amounted to SEK 241.0 million (218.6), corresponding to growth of 10 percent in SEK.• Organic growth was 23 percent in local currencies. Excluding revenue from... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion In Direct Procurement DCD Heart Transplantation | 452 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISHLT... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: Preliminary One-Year Follow-up Data From the US Preserve Trial for XVIVO's Heart Technology Presented at ISHLT in Toronto | 409 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, preliminary one-year follow-up data from the US PRESERVE trial of XVIVO's investigational... ► Artikel lesen | |
| 22.04. | Late-Breaking Data from PRESERVE Trial Evaluates XVIVO's HOPE Preservation Approach in Heart Transplantation | 433 | Business Wire | Preliminary results suggest potential to support extended preservation time and donor heart utilization XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking... ► Artikel lesen | |
| 17.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2026 | 313 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 17, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2026.... ► Artikel lesen | |
| 16.04. | XVIVO Perfusion AB: The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal | 319 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT congress, in April 2025, the one-year results from the European multicenter... ► Artikel lesen | |
| 02.04. | Xvivo Perfusion AB (publ) GAAP EPS of SEK 0.80, revenue of SEK 812.2M | 4 | Seeking Alpha | ||
| 01.04. | XVIVO Perfusion AB: Annual Report 2025 | 367 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 1, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today XVIVO Perfusion AB (publ) publish the Annual Report for 2025. The Annual Report is attached... ► Artikel lesen | |
| 19.03. | Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab | 532 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / March 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice of... ► Artikel lesen | |
| 20.02. | XVIVO Perfusion AB: The Nomination Committee's Proposal for New Board Members | 817 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / February 20, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Correction: In the press release that was distributed today at 2:00 p.m. CET, the nomination... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 30,360 | -3,80 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Carl Zeiss Meditec mit einem Kursziel von 26,10 Euro auf "Market-Perform" belassen. Dies schrieb Analystin Susannah Ludwig am... ► Artikel lesen | |
| ECKERT & ZIEGLER | 14,690 | -1,34 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| INTUITIVE SURGICAL | 358,25 | +0,15 % | TD Cowen cuts Intuitive Surgical stock price target on valuation | ||
| RHOEN-KLINIKUM | 13,000 | -2,26 % | Hochkomplexer Aorteneingriff am RHÖN-Klinikum Frankfurt (Oder) | Frankfurt (Oder) (ots) - - Offene Notfalloperation bei rupturiertem Aneurysma durchgeführt- Eingriff zählt zu den anspruchsvollsten Verfahren der GefäßchirurgieDie Klinik für Gefäßchirurgie am RHÖN-Klinikum... ► Artikel lesen | |
| BICO GROUP | 1,290 | -0,46 % | BICO Group AB: Bulletin from the Annual General Meeting in BICO Group AB (publ) | The following resolutions were passed at the Annual General Meeting (the "AGM") of BICO Group AB (publ) ("BICO" or the "Company") held today on 7 May 2026 in Gothenburg, Sweden.
Adoption of Income Statement... ► Artikel lesen | |
| M1 KLINIKEN | 18,380 | 0,00 % | Dividendenbekanntmachungen (09.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,63 USD 1,4275 EUR ALIMENTATION COUCHE-TARD INC CA01626P1484 0,215 CAD 0,1328 EUR ANPARIO PLC GB00B3NWT178 0... ► Artikel lesen | |
| BAXTER | 19,940 | +0,50 % | Baxter International's Q2 2026 Earnings: What to Expect | ||
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| JD HEALTH INTERNATIONAL | 4,129 | +3,47 % | UBS: Limited Impact From CN Pharma Retail Regulation; JD HEALTH, ALI HEALTH TPs Cut | ||
| COOPER COMPANIES | 62,89 | +0,40 % | Cooper Companies Posts Q2 Loss Hurt By One-Time Litigation Charge, Revenue Rises 8% | WASHINGTON (dpa-AFX) - Cooper Companies, Inc. (COO) on Thursday posted a net loss due to a substantial litigation-related charge tied to a 2023 product recall. However, the company reported... ► Artikel lesen | |
| LIFEWARD | 7,920 | -0,38 % | Lifeward Ltd.: Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing | HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio... ► Artikel lesen | |
| BONESUPPORT | 21,360 | -1,38 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q1 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2026.
"Solid start to 2026 - strong growth... ► Artikel lesen | |
| ONWARD MEDICAL | 2,495 | -0,99 % | ONWARD Medical NV: ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones | EINDHOVEN, the Netherlands, May 26, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD - US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function... ► Artikel lesen | |
| COMMUNITY HEALTH SYSTEMS | 3,240 | +5,88 % | COMMUNITY HEALTH SYSTEMS INC - 8-K, Current Report | ||
| RAMSAY HEALTH CARE | 26,000 | +0,78 % | RAMSAY HEALTH CARE LIMITED: Change in substantial holding |
Das Unternehmen XVIVO PERFUSION AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 25,680 Euro und damit +2,39 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.